Changes to Arrangements for Annual General Meeting

AstraZeneca PLC (the Company) today announced important changes to the arrangements for the Company’s forthcoming Annual General Meeting (AGM).

The Board of Directors of the Company has been closely monitoring the evolving COVID-19 situation. The safety and security of our workforce and our shareholders is paramount and therefore, in compliance with the ‘Stay at Home Measures’ passed into law in England and Wales on 26 March 2020, the AGM will now take place as a closed meeting at the Company’s corporate office at Academy House, 136 Hills Road, Cambridge, CB2 8PA on Wednesday 29 April 2020 at 14:30 BST. It will not be possible for shareholders to attend the meeting in person.

Shareholders are strongly encouraged to appoint the Chairman of the AGM as their proxy. This means that the Chairman of the AGM will be able to vote on their behalf, and in accordance with their instructions, at the AGM.

Further information, including about how shareholders may engage with the Board, is set out in a letter to shareholders available on the AGM section of the Company’s website, at www.astrazeneca.com/agm.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp
Company Secretary
AstraZeneca PLC

Om oss

AstraZeneca är ett globalt, innovationsdrivet bioläkemedelsföretag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom tre huvudsakliga terapiområden: cancer, kardiovaskulära sjukdomar, njursjukdomar och metabola sjukdomar och sjukdomar i andningsvägarna. AstraZeneca bedriver verksamhet i över 100 länder och dess innovativa läkemedel används av miljontals patienter över hela världen. Mer information finns på: www.astrazeneca.com och www.astrazeneca.se

Prenumerera